Teva Pharmaceutical Industries Limited Ordinary Shares (NY:TEVA)

39.53 +0.22 (+0.56%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited Ordinary Shares

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

35 36 Next >

A Closer Look at 4 Analyst Recommendations For Teva Pharmaceutical Indus ↗

October 23, 2024

Via Benzinga

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

October 22, 2024

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug ↗

October 17, 2024

Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA...

Via Benzinga

Topics Intellectual Property Lawsuit

Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes ↗

October 11, 2024

Teva Pharmaceuticals will pay $450 million to resolve allegations of kickback schemes involving Medicare copays and price-fixing. This settlement is part of a broader crackdown on healthcare fraud...

Via Benzinga

Topics Fraud

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,400 Today ↗

September 16, 2024

Via Benzinga

Key Takeaways From Teva Pharmaceutical Indus Analyst Ratings ↗

September 03, 2024

Via Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,400 Today ↗

August 21, 2024

Via Benzinga

Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today ↗

October 10, 2024

Via Benzinga

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

October 08, 2024

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected ↗

October 03, 2024

Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026.

Via Benzinga

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

October 03, 2024

From Teva Pharmaceutical Industries Ltd; mAbxience

Via GlobeNewswire

Teva Launches Generic Version Of Sandostatin In The US ↗

October 01, 2024

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) are down Tuesday. Here's what you need to know.

Via Benzinga

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

October 01, 2024

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024

September 30, 2024

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

$1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today ↗

September 30, 2024

Via Benzinga

Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast ↗

September 30, 2024

Truist Securities raises the price target for Corcept Therapeutics to $76, driven by robust Korlym sales and promising relacorilant trials. The analyst highlights significant growth potential in the...

Via Benzinga

As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse

September 24, 2024

EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END

Via FinancialNewsMedia

As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse

September 24, 2024

From FN Media Group LLC

Via GlobeNewswire

Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia

September 23, 2024

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia

September 21, 2024

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)

September 21, 2024

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva to Present at the Bank of America 2024 Global Healthcare Conference

September 11, 2024

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars ↗

September 11, 2024

UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs.

Via Benzinga

Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies ↗

September 10, 2024

Baltimore secures an $80 million settlement with Teva Pharmaceuticals in its opioid crisis litigation. Funds will be allocated to education, recovery centers, and outreach initiatives.

Via Benzinga

JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability ↗

September 06, 2024

JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris.

Via Benzinga

Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production ↗

September 06, 2024

Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally.

Via Benzinga

Organon Stock Sees Relative Strength Rating Rise To 91 ↗

August 27, 2024

On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before.

Via Investor's Business Daily

Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

August 26, 2024

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets ↗

August 23, 2024

Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite concerns, experts predict limited financial impact on companies like Pfizer,...

Via Benzinga

Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold ↗

August 20, 2024

On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier.

Via Investor's Business Daily

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.